Volpara Health Technologies' board supports the acquisition offer from Lunit, an AI cancer detection developer, at $1.15 per share—a 47.4% premium to the last closing price.
The deal values Volpara at $295.7 million.
The transaction, subject to shareholder and court approval and other conditions, is expected to enhance Volpara's capabilities in early breast cancer detection.